Pheast Raises $76M In Series A Funding To Train The Immune System To Feast On Cancer
04/26/22, 11:00 AM
Location
palo altoMoney raised
$76 million
Round Type
series a
Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has raised $76 million in Series A funding round led by Catalio Capital Management and ARCH Venture Partners. Alexandria Venture Investments and Risk and Reward (R2) also participated. Pheast plans to use the funds to expand its management, scientific, and administrative teams, as well as towards R&D to advance its pipeline of innate immune checkpoint inhibitors towards the clinic.
Company Info
Location
palo alto, california, united states
Additional Info
Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. Founded in 2020 and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is aiming to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer. Pheast can be found online at Pheast.com and on LinkedIn.